Kirave Prathibha, Gondaliya Piyush, Kulkarni Bhagyashri, Rawal Rakesh, Garg Rachana, Jain Alok, Kalia Kiran
Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Ahmedabad, Gujarat, India.
These authors contributed equally to this work and are first authors.
Oncotarget. 2020 Mar 31;11(13):1157-1171. doi: 10.18632/oncotarget.27531.
Cisplatin is used as chemotherapeutic drug for oral squamous cell carcinoma (OSCC). However, OSCC cells develop resistance following long-term cisplatin exposure. Resistance against cisplatin chemo-therapy is accredited to the process of epithelial-to-mesenchymal transition, which in-turn has been linked to tumor-recurrence. miRNA deregulation, a common event in cancer, plays contributory role in chemo-resistance. Exosomes acts as the natural cargo for miRNA and facilitates inter-cell communication in the tumor micro-environment. Hence, exosomal-mediated miRNA transference may play essential role in drug resistance and serve as a target for cancer-therapy. miR-155 upregulation in OSCC has been described, however, its relevance in the observed chemo-resistance is unclear and also, if exosomes have any role in miR-155 regulation remain elusive. In the present study, we document for the first time the critical role of exosomes in mediating increments in miR-155 expression in OSCC cells that have acquired cisplatin resistance (cis cells). Importantly, exosomal transfer from cis to the cisplatin sensitive (cis) cells was found to confer significant miR-155 induction in the recipient cis cells. Restoration of miR-155 expression in cis cells following miR-155 mimics treatment led to epithelial to mesenchymal transition, enhancements in their migratory potential as well as acquisition of resistant phenotype. Notably, similar augmentations in the migratory and chemo-resistant traits were seen upon delivery of exosomes from cis to the recipient cis cells. Overall, our findings establish the significance of exosomal-mediated miR-155 shuttling in the cisplatin-chemoresistance, commonly observed in OSCC cells, thereby providing rationale for targeting miR-155 signalling for oral cancer therapy.
顺铂用作口腔鳞状细胞癌(OSCC)的化疗药物。然而,OSCC细胞在长期接触顺铂后会产生耐药性。顺铂化疗耐药归因于上皮-间质转化过程,而这一过程又与肿瘤复发相关。miRNA失调是癌症中的常见现象,在化疗耐药中起作用。外泌体作为miRNA的天然载体,促进肿瘤微环境中的细胞间通讯。因此,外泌体介导的miRNA转移可能在耐药中起关键作用,并可作为癌症治疗的靶点。已有研究描述了OSCC中miR-155上调,然而,其与观察到的化疗耐药的相关性尚不清楚,并且外泌体是否在miR-155调节中起作用也仍不清楚。在本研究中,我们首次记录了外泌体在介导获得顺铂耐药性的OSCC细胞(顺铂耐药细胞)中miR-155表达增加方面的关键作用。重要的是,发现从顺铂耐药细胞向顺铂敏感细胞的外泌体转移可在受体顺铂敏感细胞中显著诱导miR-155。用miR-155模拟物处理后,顺铂耐药细胞中miR-155表达的恢复导致上皮-间质转化,其迁移潜能增强以及获得耐药表型。值得注意的是,当从顺铂耐药细胞向受体顺铂敏感细胞递送外泌体时,在迁移和化疗耐药特性方面也观察到类似的增强。总体而言,我们的研究结果确立了外泌体介导的miR-155穿梭在OSCC细胞中常见的顺铂化疗耐药中的重要性,从而为靶向miR-155信号通路进行口腔癌治疗提供了理论依据。